BR112014019459A8 - Proteínas de ligação à cdim e usos das mesmas - Google Patents
Proteínas de ligação à cdim e usos das mesmasInfo
- Publication number
- BR112014019459A8 BR112014019459A8 BR112014019459A BR112014019459A BR112014019459A8 BR 112014019459 A8 BR112014019459 A8 BR 112014019459A8 BR 112014019459 A BR112014019459 A BR 112014019459A BR 112014019459 A BR112014019459 A BR 112014019459A BR 112014019459 A8 BR112014019459 A8 BR 112014019459A8
- Authority
- BR
- Brazil
- Prior art keywords
- binding proteins
- cdim
- dim
- cells
- diagnostic assays
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261633330P | 2012-02-08 | 2012-02-08 | |
US61/633,330 | 2012-02-08 | ||
PCT/US2013/025430 WO2013120012A2 (en) | 2012-02-08 | 2013-02-08 | Cdim binding proteins and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112014019459A2 BR112014019459A2 (pt) | 2017-06-27 |
BR112014019459A8 true BR112014019459A8 (pt) | 2023-01-10 |
BR112014019459B1 BR112014019459B1 (pt) | 2023-04-18 |
Family
ID=48045015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014019459-9A BR112014019459B1 (pt) | 2012-02-08 | 2013-02-08 | Proteínas de ligação à cdim e usos das mesmas |
Country Status (15)
Country | Link |
---|---|
US (1) | US9409976B2 (pt) |
EP (1) | EP2812356B1 (pt) |
JP (1) | JP6335796B2 (pt) |
KR (1) | KR102102111B1 (pt) |
CN (1) | CN104254544B (pt) |
AU (1) | AU2013200903B2 (pt) |
BR (1) | BR112014019459B1 (pt) |
CA (1) | CA2863714C (pt) |
DK (1) | DK2812356T3 (pt) |
ES (1) | ES2735289T3 (pt) |
HK (1) | HK1205136A1 (pt) |
IN (1) | IN2014MN01781A (pt) |
MX (1) | MX363819B (pt) |
TW (1) | TWI606064B (pt) |
WO (1) | WO2013120012A2 (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3041862B1 (en) | 2013-09-05 | 2020-05-06 | IGM Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent ig-m antibodies |
EP3572425A1 (en) | 2013-12-17 | 2019-11-27 | AIMM Therapeutics B.V. | Means and methods for counteracting myeloproliferative or lymphoproliferative disorders |
WO2015120474A1 (en) | 2014-02-10 | 2015-08-13 | Igm Biosciences, Inc. | Iga multi-specific binding molecules |
SG11201608194VA (en) | 2014-04-03 | 2016-10-28 | Igm Biosciences Inc | Modified j-chain |
SG10202001779UA (en) | 2015-01-20 | 2020-04-29 | Igm Biosciences Inc | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
SG11201707144VA (en) * | 2015-03-04 | 2017-09-28 | Igm Biosciences Inc | Cd20 binding molecules and uses thereof |
AU2016238246B2 (en) | 2015-03-25 | 2021-05-13 | Igm Biosciences, Inc. | Multi-valent hepatitis B virus antigen binding molecules and uses thereof |
CN107847591B (zh) | 2015-04-17 | 2023-07-28 | Igm生物科学股份有限公司 | 多价人免疫缺陷病毒抗原结合分子及其应用 |
EP3355913A1 (en) | 2015-09-30 | 2018-08-08 | IGM Biosciences A/S | Binding molecules with modified j-chain |
EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
KR102343742B1 (ko) | 2016-05-09 | 2021-12-24 | 아이쥐엠 바이오사이언스 인코포레이티드 | 항-pd-l1 항체 |
IL302488A (en) * | 2016-08-15 | 2023-06-01 | Novartis Ag | Dosing regimens and methods for the treatment of multiple sclerosis using opatumumab |
US20200095327A1 (en) * | 2017-02-08 | 2020-03-26 | Dragonfly Therapeutics, Inc. | Antibody heavy chain variable domains targeting the nkg2d receptor |
WO2018148445A1 (en) | 2017-02-08 | 2018-08-16 | Adimab, Llc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
KR20240060739A (ko) | 2017-02-20 | 2024-05-08 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
EP3607091A4 (en) | 2017-04-07 | 2021-01-20 | IGM Biosciences, Inc. | MODIFIED HUMAN CONSTANT IGM REGIONS FOR THE MODULATION OF COMPLEMENT-DEPENDENT CYTOLYSIS EFFECTOR FUNCTION |
CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
KR20200128391A (ko) | 2018-03-01 | 2020-11-12 | 아이쥐엠 바이오사이언스 인코포레이티드 | IgM 혈청 반감기에 영향을 미치는 IgM Fc 및 J-쇄 돌연변이 |
EP3880714A4 (en) * | 2018-11-16 | 2022-07-20 | Memorial Sloan Kettering Cancer Center | ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF |
CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体*** |
CN114181318B (zh) * | 2021-11-08 | 2023-08-01 | 四川大学 | 一种组织特异性表达穿透血脑屏障的idua融合蛋白的重组腺相关病毒及应用 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US5246692A (en) | 1986-09-05 | 1993-09-21 | The United States Of America As Represented By The Secretary Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US5099069A (en) | 1986-09-05 | 1992-03-24 | Gansow Otto A | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
DE3920358A1 (de) * | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5460785A (en) | 1989-08-09 | 1995-10-24 | Rhomed Incorporated | Direct labeling of antibodies and other protein with metal ions |
US5124471A (en) | 1990-03-26 | 1992-06-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bifunctional dtpa-type ligand |
AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
US5417972A (en) | 1993-08-02 | 1995-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US6312691B1 (en) | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
US6962979B1 (en) | 1995-03-14 | 2005-11-08 | Cohesion Technologies, Inc. | Crosslinkable biomaterial compositions containing hydrophobic and hydrophilic crosslinking agents |
US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6680335B2 (en) | 1998-09-28 | 2004-01-20 | Sugen, Inc. | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds |
CZ2002936A3 (cs) | 1999-09-17 | 2002-10-16 | Abbott Gmbh & Co. Kg | Pyrazolopyrimidiny jako terapeutické prostředky |
US20020028178A1 (en) | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
US7319139B2 (en) | 2001-01-29 | 2008-01-15 | Biogen Idec, Inc. | TAG-72 specific CH2 domain deleted antibodies |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
US6645974B2 (en) | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
CA2476625A1 (en) * | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
US7485297B2 (en) * | 2003-08-12 | 2009-02-03 | Dyax Corp. | Method of inhibition of vascular development using an antibody |
EP1682179A4 (en) | 2003-11-05 | 2008-09-03 | Palingen Inc | INCREASED CYTOTOXICITY OF CDIM BINDING ANTIBODY AGAINST B LYMPHOCYTES |
US20120237441A9 (en) * | 2003-11-05 | 2012-09-20 | Bhat Neelima M | Enhanced b cell cytotoxicity of cdim binding antibody |
AU2005304973A1 (en) * | 2004-11-05 | 2006-05-18 | Palingen, Inc. | Antibody induced cell membrane wounding |
EP1861424B1 (en) * | 2005-03-14 | 2011-03-30 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Human monoclonal antibodies against hendra and nipah viruses |
AU2006292132A1 (en) * | 2005-09-19 | 2007-03-29 | Palingen, Inc. | Treatment of B cell diseases using anti-germline antibody binding agents |
MX2009010765A (es) * | 2007-04-02 | 2009-10-26 | Amgen Fremont Inc | Anticuerpos anti-ige. |
-
2013
- 2013-02-08 CA CA2863714A patent/CA2863714C/en active Active
- 2013-02-08 IN IN1781MUN2014 patent/IN2014MN01781A/en unknown
- 2013-02-08 ES ES13713588T patent/ES2735289T3/es active Active
- 2013-02-08 JP JP2014556751A patent/JP6335796B2/ja active Active
- 2013-02-08 US US13/763,398 patent/US9409976B2/en active Active
- 2013-02-08 CN CN201380008515.XA patent/CN104254544B/zh active Active
- 2013-02-08 EP EP13713588.5A patent/EP2812356B1/en active Active
- 2013-02-08 BR BR112014019459-9A patent/BR112014019459B1/pt active IP Right Grant
- 2013-02-08 WO PCT/US2013/025430 patent/WO2013120012A2/en active Application Filing
- 2013-02-08 MX MX2014009628A patent/MX363819B/es active IP Right Grant
- 2013-02-08 KR KR1020147025110A patent/KR102102111B1/ko active IP Right Grant
- 2013-02-08 TW TW102105337A patent/TWI606064B/zh active
- 2013-02-08 DK DK13713588.5T patent/DK2812356T3/da active
- 2013-02-08 AU AU2013200903A patent/AU2013200903B2/en active Active
-
2015
- 2015-06-09 HK HK15105490.7A patent/HK1205136A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP2812356A2 (en) | 2014-12-17 |
JP2015511817A (ja) | 2015-04-23 |
US9409976B2 (en) | 2016-08-09 |
MX2014009628A (es) | 2015-03-19 |
ES2735289T3 (es) | 2019-12-17 |
CN104254544A (zh) | 2014-12-31 |
HK1205136A1 (en) | 2015-12-11 |
CN104254544B (zh) | 2017-04-26 |
WO2013120012A2 (en) | 2013-08-15 |
IN2014MN01781A (pt) | 2015-07-03 |
CA2863714A1 (en) | 2013-08-15 |
JP6335796B2 (ja) | 2018-06-06 |
TW201345921A (zh) | 2013-11-16 |
AU2013200903B2 (en) | 2015-05-14 |
AU2013200903A1 (en) | 2013-08-22 |
BR112014019459A2 (pt) | 2017-06-27 |
CA2863714C (en) | 2022-07-05 |
KR102102111B1 (ko) | 2020-04-20 |
BR112014019459B1 (pt) | 2023-04-18 |
US20140044739A1 (en) | 2014-02-13 |
KR20150001728A (ko) | 2015-01-06 |
MX363819B (es) | 2019-04-03 |
EP2812356B1 (en) | 2019-03-27 |
TWI606064B (zh) | 2017-11-21 |
DK2812356T3 (da) | 2019-07-08 |
WO2013120012A3 (en) | 2013-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014019459A8 (pt) | Proteínas de ligação à cdim e usos das mesmas | |
CR20190095A (es) | Nuevos receptores de linfocitos t e inmonoterapia basada en el uso de los mismos | |
BR112016030462A2 (pt) | moléculas de ligação, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula de ligação, composição farmacêutica, uso da molécula de ligação, método de tratamento de doenças e de indução da lise de células alvo | |
CL2017002767A1 (es) | Nuevas proteínas específicas para cd137. | |
PH12015501092A1 (en) | Anti-ceacam5 antibodies and uses thereof | |
BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
PH12019500439A1 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
BR112013019975A2 (pt) | proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira" | |
EA201590998A1 (ru) | СВЯЗЫВАЮЩИЕСЯ С EGFR И c-Met МОЛЕКУЛЫ С ДОМЕНАМИ ФИБРОНЕКТИНА ТИПА III | |
BR112016016658A2 (pt) | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão | |
CL2021000207A1 (es) | Nuevas proteínas de fusión específicas para cd137 y pd-l1 | |
AR092818A1 (es) | Anticuerpo tau humanizado | |
BR112014019116A8 (pt) | Kit, moléculas de anticorpo, composição farmacêutica, métodos de tratamento, usos, vetor, célula hospedeira e método de produção de uma molécula de anticorpo | |
MX2017014716A (es) | Polipeptido de fusion anti-cancer. | |
BR112015017800A2 (pt) | moléculas de ligação ao antígeno biespecífica ativadora de célula t, polinucleotídeo, polipeptídeo, vetor, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t | |
UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
BR112014015851A2 (pt) | proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17 | |
BR112015011158A2 (pt) | triazolopirazina | |
BR112013031892A2 (pt) | anticorpos anti-psgl-1 e seu uso | |
EA201492067A1 (ru) | Применение связывающих семафорин-4d молекул для промотирования нейрогенеза после инсульта | |
BR112017012588B8 (pt) | Compostos heteroaril-heteroarila bicíclicos de ácido benzoico, seus usos, composições farmacêuticas, métodos de preparação destas e métodos para provocar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e para ativar o receptor beta do ácido retinoico | |
BR112017026292A2 (pt) | muteína de lipocalina, molécula de ácido nucleico, vetor de expressão, célula hospedeira, método de produção de muteína de lipocalina, métodos de ligação de lag-3 em pacientes, de estímulo da reação imunológica em pacientes, de indução da proliferação de linfócitos t, de interferir com a ligação de lag-3 humano e de detecção da presença de lag-3, composição farmacêutica, imunoconjugado, uso de muteína e kit analítico ou de diagnóstico | |
BR112015006363A2 (pt) | combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r | |
BR112014029302A2 (pt) | método de redução de peso | |
AR115878A1 (es) | Proteínas de fusión específicas para cd137 y pd-l1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: IGM BIOSCIENCES A/S (DK) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B25A | Requested transfer of rights approved |
Owner name: IGM BIOSCIENCES, INC. (US) |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: IGM BIOSCIENCES, INC. (US) |
|
B25A | Requested transfer of rights approved |
Owner name: MCURE BIOSCIENCES INC. (US) |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/02/2013, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |